Elevated homocysteine levels are associated with increased ischemic myocardial injury in acute coronary syndromes  by Al-Obaidi, Mohamed K et al.
Elevated Homocysteine Levels Are
Associated With Increased Ischemic
Myocardial Injury in Acute Coronary Syndromes
Mohamed K. Al-Obaidi, MD, MRCP, Peter J. Stubbs, MD, MRCP, Paul Collinson,*
Ronan Conroy, BMUS,† Ian Graham, FRCPI,† Mark I. M. Noble, DSC, MD
London, United Kingdom, and Dublin, Ireland
OBJECTIVES This study was conducted to determine whether the amount of myocardial damage during
acute coronary syndromes (ACS) is related to the admission plasma homocysteine concen-
tration.
BACKGROUND Elevated homocysteine levels are associated with increased thrombosis in patients presenting
with ACS. It is not known whether this association is reflected in the degree of myocardial
injury in those patients.
METHODS We studied consecutive patients presenting with acute myocardial infarction (MI) (n 5 205)
and unstable angina pectoris (UAP) (n 5 185). Plasma samples were collected on admission
and prior to clinical intervention and were assayed for homocysteine by high performance
liquid chromatography (HPLC). Myocardial necrosis was assessed by measurements of
cardiac troponin T (cTnT) on admission and 12 h after admission (peak cTnT). The patients
were studied by quintiles of homocysteine concentration.
RESULTS There was a significant increase in peak cTnT in the 5th homocysteine quintile in MI
(analysis of variance [ANOVA], p 5 0.005), the levels being 4.10, 3.86, 4.13, 6.20 and
7.85 mg/liter for quintiles 1 to 5, respectively (p , 0.0001, for top vs. bottom quintile).
Similarly, there was a step-up in peak cTnT levels in the top homocysteine quintile in UAP
(ANOVA, p , 0.0001), the levels being 0.03, 0.03, 0.02, 0.04 and 0.15 mg/liter, (p , 0.0001
for top vs. bottom quintile). In a multivariate regression model, the association between peak
cTnT and the top homocysteine quintile remained strong after adjustment of other
confounders including age, gender, final diagnosis and thrombolysis treatment (odds ratio
[OR]: 2.92 (1.75–4.87) p , 0.0001). The patients with UAP were further examined
according to peak cTnT levels below (cTnT negative) or above (cTnT positive) 0.1 mg/liter.
Homocysteine levels were significantly higher in cTnT positive than cTnT negative patients;
13.8 (11.7–15.3) vs. 10.3 (9.4–11.3) mmol/liter, respectively, p 5 0.002.
CONCLUSIONS Elevated homocysteine levels are associated with a higher risk of ischemic myocardial injury
in patients presenting with ACS. (J Am Coll Cardiol 2000;36:1217–22) © 2000 by the
American College of Cardiology
Moderate elevation of plasma homocysteine concentrations
has been reported to be an independent risk factor in the
development of coronary artery disease (1,2). Many of the
reported effects of plasma homocysteine are thought to be
mediated by its atherogenic and prothrombotic properties
(3,4). These were clearly evident in patients suffering from
the congenital disorder of homocystinuria where marked
elevation of plasma homocysteine was accompanied by
widespread atherosclerosis and vascular thrombotic events at
an early stage in life (5).
Patients with angiographically determined coronary artery
disease have been reported to experience a concentration
dependent increase in the risk of death with increasing homo-
cysteine concentration (6). The mechanisms of this increase in
mortality risk have not, however, been determined. It is known
that atherosclerotic coronary artery disease may progress un-
detected with no serious threat to life. In contrast, the devel-
opment of acute coronary syndromes (ACS) of myocardial
infarction (MI) and unstable angina pectoris (UAP) mark a
significant rise in the risk of death and long-term morbidity
(7). We have recently reported an association between homo-
cysteine concentrations and plasma markers of thrombosis
activation in patients presenting with ACS (8). These results
have led us to postulate that elevated homocysteine concentra-
tions would lead to increased myocardial injury in this patient
group.
In the present study we investigated the relationship
between homocysteine concentrations determined on ad-
mission in patients presenting with acute MI or UAP and
the degree of myocardial necrosis. The latter is estimated by
measurement of admission and peak plasma release of the
structural cardiac protein troponin T (cTnT).
METHODS
The study population consisted of patients presenting to a
single coronary care unit with clinical signs of acute coro-
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nary ischemia; they were consecutively recruited between
1990–1994 in a London teaching hospital. The study was
approved by the Hospital Ethical Committee, and patients
agreed to additional blood being taken, during routine
venesection, after receiving informed consent.
Myocardial infarction was diagnosed according to the
World Health Organization (WHO) criteria (9). Unstable
angina pectoris was diagnosed if the WHO criteria for MI
were not met: all enzyme measurements (creatine kinase,
CK; aspartate transaminase, AST; hydroxybutyrate dehy-
drogenase, HBD) were below twice their upper reference
range throughout the routine sampling period (daily for
three days). Evidence of ischemic heart disease was dem-
onstrated by either follow-up cardiac event (death, coronary
revascularization or MI), a positive exercise treadmill test
(.0.1 mV ST segment depression 80 ms after the J point)
or demonstration of ischemia on thallium radioisotopic
scanning. Patients with atypical symptoms and a positive
exercise test were subjected to coronary angiography and
shown to have normal coronary arteries; these patients were
not included in the present study. Patients with typical
symptoms of ACS, however, were exercised if the resting
electrocardiogram (ECG) was equivocal; if typical ischemic
ST depression occurred, we felt confident of a UAP
diagnosis.
Full clinical, biochemical, and management investiga-
tions performed were recorded on all patients. Clinical
details included risk factor assessment for coronary artery
disease. Smoking status was classified as current smokers
and nonsmokers; current smokers included individuals who
stopped less than four weeks before entry into the study. A
known history of hypertension and/or diabetes mellitus and
the treatment received before admission were also recorded.
Routine lipid profile estimation was carried out on admis-
sion for all patients, documenting their total cholesterol and
triglyceride levels.
Patients admitted to the coronary care unit underwent
daily sampling for three days for the routine cardiac enzyme
protocol in the hospital (CK, AST, HBD). For the present
study further samples were taken for research purposes
approved by the local ethical committee. Venous blood
samples were obtained on admission from a cuffed antecu-
bital vein before initiation of thrombolysis or anticoagulant
treatment. Within 15 min of collection, platelet-poor
plasma was obtained by centrifugation for 15 min at room
temperature at 3,000g and flash-frozen on dry ice before
transfer to a 280°C freezer pending batch analysis. A
further sample was obtained after 12 h from admission, the
time point when cardiac cTnT is most efficient for diagnos-
ing myocardial damage in this population (10). All man-
agement decisions were made without knowledge of pa-
tients’ cTnT or homocysteine results. All samples were
batch-assayed for cTnT and homocysteine by two different
operators and were blinded from the final diagnostic clas-
sification.
Homocysteine assay. Plasma total homocysteine, which
includes the sum of protein-bound and free homocysteine,
was measured by high-performance liquid chromatography
with fluorescence detection (11,12). The coefficients of
variation within and between days for the assays were 5% or
less. Plasma homocysteine was recorded in units of mmol/
liter.
Plasma homocysteine measurement on admission in a
separate group of patients with MI (n 5 22) showed a
median, in mmol/liter, with 25th to 75th interquartile range
of 11.9 (10.7–12.6) on admission and of 11.5 (9.1–13.4) on
day 2. Day 2 is the first measurement in published data on
changes following an acute coronary syndrome (13). A letter
to the Lancet shows a slight decrease on day 2 compared
with admission, compatible with our results (14).
Troponin-T assay. Cardiac-specific troponin T was deter-
mined by an enzyme-linked immunosorbent assay (ELISA)
using an ES-300 immunoassay analyzer (Boehringer Mann-
heim, Lewes, Sussex) as previously described (10). The
detection limit for the assay was 0.01 mg/liter. The inter-
assay coefficient of variation was 12.3%, 7.7% and 4.2% at
mean cTnT levels of 0.13, 1.6 and 7.1 mg/liter, respectively.
The intra-assay coefficient of variation was 2.0% and 1.9%
at mean cTnT values of 1.7 and 7.0 mg/liter, respectively.
Statistical analysis. Homocysteine and cTnT values were
logarithmically transformed; the latter followed a censored
log-normal distribution with values less than 0.01 and
greater than 40 mg/liter, representing the limits of measure-
ments. Values for homocysteine and cTnT are expressed as
geometric means (95% confidence interval [CI]). Qualita-
tive values for cTnT were determined by categorizing the
patients above (troponin-T positive) and below (troponin-T
negative) the cTnT value of 0.1 mg/liter. This cutoff value
has often been reported to signify future cardiac morbidity
and mortality in ACS (15,16). Homocysteine values were
categorized into quintiles (interquintile ranges 8.50, 10.20,
12.26, 15.8 mmol/liter in ACS; 8.40, 10.20, 12.20,
15.70 mmol/liter in UAP; and 8.50, 10.18, 12.60, 16.46
mmol/liter in MI). Differences between categorical variables
were tested using the chi-square test. Group comparisons of
the log-transformed values were made by independent
sample t test for two groups and analysis of variance
Abbreviations and Acronyms
ANOVA 5 analysis of variance
ACS 5 acute coronary syndromes
AST 5 aspartate transaminase
CI 5 confidence interval
CK 5 creatine kinase
cTnT 5 cardiac troponin T
ECG 5 electrocardiogram
ELISA 5 enzyme-linked immunoabsorbent assay
HBD 5 hydroxybutyrate dehydrogenase
MI 5 myocardial infarction
UAP 5 unstable angina pectoris
WHO 5 World Health Organization
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(ANOVA) for more than two groups. In the latter situation,
differences between individual groups were then determined
by a post hoc Dunnett test. Multivariate regression analysis
of continuous variables was made using a linear regression
model and of categorical variables using a logistical regres-
sion model. All reported probability values are two-sided.
Analyses were performed using SPSS for Windows.
RESULTS
A total of 390 consecutive patients presenting with ACS
(MI, n 5 205; UAP, n 5 185) were studied. Table 1 shows
the basic characteristics of the patient groups. Patients
presenting with MI were of older age, whereas patients with
UAP had a more frequent history of prior MI. Otherwise,
risk factor profiles were similar in both groups. Myocardial
injury was significantly more prominent in patients with MI
than UAP as expected and as evidenced by higher peak CK,
AST, HBD levels and also by higher admission and peak
cTnT levels. Homocysteine concentrations were not differ-
ent between the two groups.
The relationship between homocysteine and cTnT was
first examined by categorizing the patients according to
quintiles of admission homocysteine. Figure 1 shows the
relationship between cTnT concentrations on admission in
relation to homocysteine quintiles. There was no significant
difference in cTnT levels in MI (Fig. 1a) (0.08, 0.09, 0.10,
0.05 and 0.20 mg/liter for quintiles 1 to 5, respectively,
ANOVA, p 5 NS) or in UAP (Fig. 1b) (0.02, 0.02, 0.02,
0.02 and 0.03 mg/liter for quintiles 1 to 5, respectively,
ANOVA, p 5 NS). However, when the two groups were
combined (Fig. 1c), there was an increase in cTnT levels in
the upper homocysteine quintile (0.04, 0.05, 0.04, 0.03 and
0.08 mg/liter for quintiles 1 to 5, respectively, ANOVA, p 5
0.02). The likelihood of a troponin-T positive status in
patients within the top homocysteine quintile versus the
bottom four quintiles was 58% and 40% in MI (p 5 0.07),
and 25% versus 12% in UAP (p , 0.05).
The association between homocysteine concentrations
and cTnT was more prominent when the latter reached its
maximal values. Figure 2 illustrates a significant elevation in
peak cTnT in the 5th homocysteine quintile in MI (Fig. 2a,
ANOVA, p 5 0.005; 4.10, 3.86, 4.13, 6.20 and
7.85 mg/liter for quintiles 1 to 5, respectively [p , 0.0001],
for top vs. bottom quintile). Similarly, there was a rise in
peak cTnT levels in the top homocysteine quintile in UAP
(Fig. 2b, ANOVA, p , 0.0001; 0.03, 0.03, 0.02, 0.04 and
0.15 mg/liter [p , 0.0001] for top vs. bottom quintile).
Figure 2c shows the same analysis with both groups com-
bined together (ANOVA, p , 0.0001).
Table 2 shows a multivariate regression analysis with peak
cTnT as the dependent variable in the ACS patients. The
cTnT levels were influenced by greater age, thrombolysis, a
final diagnosis of MI and homocysteine levels in the 5th
quintile.
Figure 1. Admission cTnT levels by quintiles of admission homocysteine
in patients with (a) MI, (b) UAP, and (c) all ACS patients.
Table 1. Basic Characteristics of the Study Groups
MI UAP
Age (yrs) 61.8 6 0.74 59.2 6 0.85
Men (% total) 78 71
Previous MI (% total) 20 34
Hypertension (% total) 26 28
Diabetes mellitus (% total) 17 12
Current smoking (% total) 37 35
Worsening angina (% total) 10 15
ST elevation (% total) 54 5
Admission systolic pressure (mm Hg) 138.9 6 1.9 139.7 6 2.4
Pulse rate (/min) 83.1 6 1.4 85.1 6 1.8
Killip score 10.1 6 0.23 8.6 6 0.21
Peak CK (U/liter) 504 6 38 74 6 4
Peak AST (U/liter) 324 6 18 37 6 2
Peak HBD (U/liter) 645 6 52 159 6 3
Admission TnT (mg/liter) 0.10 6 1.16 0.02 6 1.1
Admission TnT .0.1 mg/liter (% total) 46 15
Peak TnT (mg/liter) 4.99 6 1.10 0.04 6 1.1
Peak TnT .0.1 mg/liter (% total) 100 32
homocysteine (mmol/liter) 11.3 6 1.3 11.2 6 1.4
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The number of UAP patients with a positive cTnT on
admission (14%) more than doubled when cTnT was
measured at the peak time point (29%), p , 0.0001. No
differences were seen in homocysteine concentration be-
tween admission cTnT negative and cTnT positive UAP
patients (11.2 [10.6–11.9] vs. 12.6 [10.8–14.7] mmol/liter,
respectively, p 5 0.14). In contrast, homocysteine concen-
trations were significantly higher in peak cTnT positive
compared to peak cTnT negative patients (13.8 [11.7–15.3]
vs. 10.3 [9.4–11.3] mmol/liter, respectively, p 5 0.002).
The likelihood of a peak troponin T positive status in UAP
in the top homocysteine quintile versus bottom four quin-
tiles was 62% versus 24%, p , 0.0001. In a multivariate
logistic regression analysis, homocysteine concentrations in
the top quintile were the strongest predictor of positive peak
cTnT status in UAP (Table 3).
We carried out an analysis of other biochemical markers
of myocardial injury by quintiles of homocysteine, which
showed CK, AST and HBD are higher in the top homo-
cysteine quintile than in the others; however, the p value
from the ANOVA was greater than 0.05. These less
clear-cut results are presumably related to the nonspecificity
of these markers.
DISCUSSION
The main outcome of the present study was a significant
association demonstrated between elevated homocysteine
and peak cTnT levels in UAP and MI patients. Threshold
levels of 16.5 mmol/liter in MI and 15.7 mmol/liter in UAP
were strong and independent predictors of ischemic myo-
cardial necrosis in those patient groups.
We have used the WHO definition of MI (based on CK)
because it is generally accepted (until it is replaced), but
obviously cTnT is a specific biochemical marker while CK
is not. However, we have shown that within the range of
cTnT in unstable angina (below 0.2 mg/liter) there is a
variable release of cTnT, with those patients who develop
levels between 0.1 and 0.2 at higher risk (17,18). This is in
a range of cTnT that approximately corresponds to negative
CK. Although we believe these patients do not
Figure 2. Peak cTnT levels by quintiles of admission homocysteine in
patients with (a) MI, (b) UAP, and (c) all ACS patients.





Intervals Z p Value
Age 0.039 0.019–0.059 3.779 ,0.0001
Male gender 0.215 20.264–0.695 0.879 0.379
Current smoking 0.282 20.159–0.725 1.254 0.210
Thrombolysis 1.135 0.658–1.614 4.656 ,0.0001
Final diagnosis 5.155 4.664–5.646 20.582 ,0.0001
Homocysteine quintile (5) 1.072 0.561–1.583 4.113 ,0.0001
Table 3. Multivariate Logistic Regression Model of Positive
Peak cTnT Status (.0.1 mg/liter) With the Legend Variables








Age 1.04 1.00–1.07 0.02
Male gender 1.03 0.47–2.27 0.92
Hypertension 1.29 0.59–2.81 0.52
Current smoking 1.29 0.59–2.80 0.52
Accelerated angina 0.90 0.35–2.34 0.83
Homocysteine quintile (2) 2.04 0.67–6.22 0.21
Homocysteine quintile (3) 0.87 0.27–2.87 0.82
Homocysteine quintile (4) 1.43 0.46–4.41 0.53
Homocysteine quintile (5) 7.32 2.26–23.71 ,0.0001
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have thrombotic coronary occlusion, we do believe they have
intracoronary thrombosis leading to peripheral emboliza-
tion, which causes cTnT release. We believe these patients
need aggressive nonthrombolytic treatment (e.g., IIb/IIIa
antagonism). Our main excitement from the present study is
that in this range, in UAP, myocardial damage could be
determined, at least partly, by homocysteine concentration,
homocysteine being prothrombotic (8).
It is assumed above that homocysteine is the independent
variable and that cTnT is dependent upon homocysteine. At
a single time point, one might argue the opposite, namely
that the increased cTnT is causing the elevated homocys-
teine. This question is resolved by examining the time
courses of change of the two variables. All the published
data deal with changes from a first sample on the day after
patient admission to later levels. There are no published
data on changes from admission day to the day after
admission. We do not have such data in the present study,
only the values for the admission day.
However, we have performed another study (19) on a
different cohort of patients that clearly shows homocysteine
levels do not change from admission day to the following
day. They do not change from the time of basal cTnT
measurement and the time of measurement of peak tropo-
nin. The only other data are found in a letter to the Lancet
(14), which are entirely consistent with our own. Thus, we
can state that the rise of cTnT, consequent upon admission
conditions, occurs at a constant level of one of those
conditions, namely homocysteine; we are describing in the
present article a situation in which troponin rises to a higher
peak when background homocysteine remains at a steady
higher level throughout the period of study.
The rise in cTnT levels was most notably observed in the
top homocysteine quintile in both MI and UAP. This
suggests the relationship between homocysteine and peak
cTnT to be a threshold rather than a concentration-related
association. This contrasts with our previous finding of a
concentration-related association between homocysteine
and activation of thrombosis in similar (different) patient
group (8). Although thrombosis plays an important patho-
physiological role in acute coronary artery occlusion, the
degree of myocardial injury culminates from the interaction
of several factors in addition to thrombus formation, includ-
ing the duration of ischemia, physical characteristics of the
plaque, coronary vascular spasm and the extent of collateral
circulation (20). Homocysteine, in contrast, may enhance
myocardial tissue injury by more than its prothrombotic
effects. Both experimental (21) and recent clinical (22,23)
evidence have shown that homocysteine adversely affects
endothelial-dependent vasodilation, thereby possibly further
limiting coronary flow reserve during acute coronary occlu-
sion.
In the present study we used both qualitative and quan-
titative cTnT values on admission and at the peak time
point to study the relationship with homocysteine. Despite
a trend toward higher admission cTnT values in the top
homocysteine quintile, the relationship with homocysteine
was significantly more prominent when cTnT levels were
taken at the peak time point, reflecting a stronger associa-
tion between homocysteine and the final myocardial injury/
infarct size. Levels of cTnT begin to rise 3 to 6 h after the
onset of ischemic injury, and they reach a peak by 12 to
24 h, with levels remaining elevated for four to five days
thereafter (24,25). Admission levels are therefore useful for
diagnostic purposes in confirming the presence of myocar-
dial injury, but they are not useful for estimating the degree
of myocardial damage. The latter is more reliably related to
the maximal rise in cTnT level (10,26).
The utilization of cTnT as a marker of myocardial injury
has significantly improved the diagnostic accuracy of acute
ischemic events, especially in the settings of equivocal
clinical presentation and/or nonspecific ECG changes (15).
However, because of the release-kinetic characteristics
described earlier, qualitative (values above or below 0.1 to
0.2 mg/liter) rather than quantitative assays have been
advocated more in the clinical setting for both diagnostic
and predictive purposes. Therefore, using a defined cut of
value, both early (17,18) and peak detection (16) of cTnT
(troponin-T positive) in patients with or without ST seg-
ment elevation have been shown to predict a worst short-
and long-term outcome in patients presenting with acute
coronary events. In our study, homocysteine levels were
clearly elevated in cTnT positive patients, especially in
UAP. This result is in agreement with the previous finding
of a relationship between homocysteine and mortality in
patients with angiographically determined coronary artery
disease (6) and in patients presenting with ACS (27).
Homocysteine concentrations can readily be lowered with
either folic acid or vitamin B6 supplementation or a com-
bination of both. Current trials are underway to assess the
effect of vitamin supplementation on the development/
progression of coronary artery disease. Our results suggest
further studies are required to assess the effect of homocys-
teine lowering treatment during acute coronary events on
the degree of myocardial injury.
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